Teleflex Incorporated (TFX) Receives $302.00 Average Target Price from Analysts

Shares of Teleflex Incorporated (NYSE:TFX) have earned an average recommendation of “Buy” from the twelve research firms that are presently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $307.11.

A number of analysts recently weighed in on the stock. UBS Group increased their price target on shares of Teleflex to $350.00 and gave the company a “buy” rating in a research report on Friday, March 22nd. Morgan Stanley increased their price target on shares of Teleflex from $295.00 to $305.00 and gave the company an “overweight” rating in a research report on Wednesday, January 2nd. Zacks Investment Research upgraded shares of Teleflex from a “sell” rating to a “hold” rating in a research report on Tuesday, February 26th. Raymond James increased their price target on shares of Teleflex from $320.00 to $348.00 and gave the company a “strong-buy” rating in a research report on Wednesday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $325.00 price target on shares of Teleflex in a research report on Tuesday.

Shares of NYSE:TFX opened at $302.16 on Wednesday. The company has a market capitalization of $13.81 billion, a P/E ratio of 30.52, a PEG ratio of 2.02 and a beta of 1.06. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.39 and a current ratio of 2.12. Teleflex has a fifty-two week low of $226.02 and a fifty-two week high of $305.92.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, February 21st. The medical technology company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.76 by $0.01. The business had revenue of $641.60 million for the quarter, compared to the consensus estimate of $641.06 million. Teleflex had a net margin of 8.20% and a return on equity of 18.47%. Teleflex’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period last year, the company posted $2.44 EPS. On average, analysts forecast that Teleflex will post 11.02 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, March 15th. Investors of record on Friday, March 1st were paid a dividend of $0.34 per share. The ex-dividend date was Thursday, February 28th. This represents a $1.36 dividend on an annualized basis and a yield of 0.45%. Teleflex’s payout ratio is 13.74%.

In related news, Director Benson Smith sold 8,500 shares of the stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $300.15, for a total transaction of $2,551,275.00. Following the completion of the sale, the director now directly owns 84,913 shares of the company’s stock, valued at approximately $25,486,636.95. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Stuart A. Randle sold 4,000 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $290.52, for a total value of $1,162,080.00. Following the sale, the director now directly owns 7,421 shares of the company’s stock, valued at $2,155,948.92. The disclosure for this sale can be found here. Over the last three months, insiders have sold 19,676 shares of company stock valued at $5,776,205. 2.56% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Exane Derivatives bought a new stake in Teleflex during the 4th quarter worth approximately $41,000. Bronfman E.L. Rothschild L.P. increased its stake in Teleflex by 17.7% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 239 shares of the medical technology company’s stock worth $62,000 after purchasing an additional 36 shares in the last quarter. Valeo Financial Advisors LLC increased its stake in Teleflex by 42.2% during the 4th quarter. Valeo Financial Advisors LLC now owns 337 shares of the medical technology company’s stock worth $87,000 after purchasing an additional 100 shares in the last quarter. Simplex Trading LLC grew its stake in shares of Teleflex by 6,466.7% during the 4th quarter. Simplex Trading LLC now owns 394 shares of the medical technology company’s stock worth $101,000 after acquiring an additional 388 shares in the last quarter. Finally, Bremer Trust National Association bought a new position in shares of Teleflex during the 4th quarter worth approximately $116,000. 91.92% of the stock is owned by institutional investors and hedge funds.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Featured Story: Trading Strategy Methods and Types

Analyst Recommendations for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.